| Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls MD Goldman, RA Marrie, JA Cohen Multiple Sclerosis Journal 14 (3), 383-390, 2008 | 712 | 2008 |
| Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open … R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ... The Lancet Neurology 17 (5), 405-415, 2018 | 325 | 2018 |
| Validity of performance scales for disability assessment in multiple sclerosis RA Marrie, M Goldman Multiple Sclerosis Journal 13 (9), 1176-1182, 2007 | 298 | 2007 |
| Phase 2 trial of ibudilast in progressive multiple sclerosis RJ Fox, CS Coffey, R Conwit, ME Cudkowicz, T Gleason, A Goodman, ... New England Journal of Medicine 379 (9), 846-855, 2018 | 265 | 2018 |
| Cell-based therapeutic strategies for multiple sclerosis NJ Scolding, M Pasquini, SC Reingold, JA Cohen Brain 140 (11), 2776-2796, 2017 | 178 | 2017 |
| Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world MD Goldman, RW Motl, J Scagnelli, JH Pula, JJ Sosnoff, D Cadavid Neurology 81 (21), 1856-1863, 2013 | 169 | 2013 |
| Possible clinical outcome measures for clinical trials in patients with multiple sclerosis MD Goldman, RW Motl, RA Rudick Therapeutic advances in neurological disorders 3 (4), 229-239, 2010 | 158 | 2010 |
| Multiple sclerosis progression: time for a new mechanism-driven framework T Kuhlmann, M Moccia, T Coetzee, JA Cohen, J Correale, J Graves, ... The Lancet Neurology 22 (1), 78-88, 2023 | 156 | 2023 |
| Walking impairment in patients with multiple sclerosis: exercise training as a treatment option RW Motl, MD Goldman, RHB Benedict Neuropsychiatric disease and treatment, 767-774, 2010 | 154 | 2010 |
| Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders O Ciccarelli, JA Cohen, SC Reingold, BG Weinshenker, MP Amato, ... The Lancet Neurology 18 (2), 185-197, 2019 | 131 | 2019 |
| Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. RJ Fox, F Bethoux, MD Goldman, JA Cohen Cleveland Clinic journal of medicine 73 (1), 91-102, 2006 | 129 | 2006 |
| The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis D Cadavid, JA Cohen, MS Freedman, MD Goldman, HP Hartung, ... Multiple Sclerosis Journal 23 (1), 94-105, 2017 | 118 | 2017 |
| Leptin indirectly affects estrous cycles by increasing metabolic fuel oxidation JE Schneider, MD Goldman, S Tang, B Bean, H Ji, MI Friedman Hormones and behavior 33 (3), 217-228, 1998 | 118 | 1998 |
| Physical inactivity, neurological disability, and cardiorespiratory fitness in multiple sclerosis RW Motl, M Goldman Acta neurologica scandinavica 123 (2), 98-104, 2011 | 112 | 2011 |
| Pilot study of a ketogenic diet in relapsing-remitting MS JN Brenton, B Banwell, AGC Bergqvist, D Lehner-Gulotta, L Gampper, ... Neurology: Neuroimmunology & Neuroinflammation 6 (4), e565, 2019 | 107 | 2019 |
| Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study DH Miller, RJ Fox, JT Phillips, M Hutchinson, E Havrdova, M Kita, ... Neurology 84 (11), 1145-1152, 2015 | 81 | 2015 |
| Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial BAC Cree, G Cutter, JS Wolinsky, MS Freedman, G Comi, G Giovannoni, ... The Lancet Neurology 19 (12), 988-997, 2020 | 80 | 2020 |
| Clinical importance of steps taken per day among persons with multiple sclerosis RW Motl, LA Pilutti, YC Learmonth, MD Goldman, T Brown PloS one 8 (9), e73247, 2013 | 75 | 2013 |
| Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis RJ Fox, CS Coffey, ME Cudkowicz, T Gleason, A Goodman, EC Klawiter, ... Contemporary clinical trials 50, 166-177, 2016 | 74 | 2016 |
| Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data MD Goldman, NG LaRocca, RA Rudick, LD Hudson, PS Chin, GS Francis, ... Neurology 93 (21), e1921-e1931, 2019 | 71 | 2019 |
